<DOC>
	<DOCNO>NCT00584974</DOCNO>
	<brief_summary>To determine safety , efficacy tolerability SEP-225289 subject Major Depressive Disorder</brief_summary>
	<brief_title>A Safety , Efficacy Tolerability Study SEP-225289</brief_title>
	<detailed_description>This randomize , placebo-controlled , double-dummy , multi-center study safety , efficacy tolerability SEP-225289 male female subject MDD . Subjects meet DSM-IV criterion Melancholic Atypical Features specifier eligible participation . The study consist screening period , may last 2 week , eight week ( 56 day ) double-blind treatment period , two week ( 14 day ) wash-out , one week ( 7 day ) follow . Total subject participation approximately 91 day ( 13 week ) . This study previously post Sepracor Inc . In October 2009 , Sepracor Inc. acquire Dainippon Sumitomo Pharma. , October 2010 , Sepracor Inc 's name change Sunovion Pharmaceuticals Inc .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>The duration current episode must least 1 month longer 12 month . Subjects must primary diagnosis Major Depressive Disorder . Subjects must least one previous , diagnosed episode MDD past 5 year . MDD must condition chiefly responsible motivating subject seek treatment . Subject general good health . Subject participating , participate , plan participate investigational drug study . Subject donate blood within last 30 day plan donate blood 30 day follow participation . Known failure respond ( past 5 year ) two adequate ( dose duration ) antidepressant medication distance mechanism action include tricyclic . Subjects undergone Electroconvulsive Therapy treatment . Treatment fluoxetine , 6 week baseline . Subject psychotic disorder , anorexia nervosa , bulimia posttraumatic stress disorder . Subject history presence bipolar disorder ( i.e. , current past history manic episode ) . Subjects Obsessive Compulsive Disorder . Subjects lifetime diagnosis Panic Disorder . Subject receive treatment antidepressant within 2 week . Subject lifetime history suicidal attempt , alcohol dependence abuse , drug ( ) dependence abuse ( exclude nicotine caffeine ) positive urine drug screen . Subject history significant risk suicide homicide . Bereavement Defined death love one within 3 month . Subject documented history HIV , hepatitis B hepatitis C .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Depression</keyword>
	<keyword>Mental Disorders</keyword>
	<keyword>Mood Disorders</keyword>
	<keyword>Depressive Disorder , Major</keyword>
	<keyword>Dysthymic Disorder</keyword>
</DOC>